PSTI Pluristem Therapeutics Inc

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
EN
01/10/2020

Underlying

PSTIPluristem Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pluristem Therapeutics Inc

 PRESS RELEASE
Free
PSTI Pluristem Thera...

Pluri CEO Issues Shareholder Update

Pluri CEO Issues Shareholder Update HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Pluri: One simple, short word of Greek origin that encapsulates the strategic evolution for our Company. This is our new name. Today, I am proud to share the vision of Pluri: to help pioneer a biotech revolution to create a range of next-generation cell-ba...

July 25, 2022 1 EN
 PRESS RELEASE
Free
PSTI Pluristem Thera...

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflectin...

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries As of July 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting global wellbeing and sustainabilityVisit our new Company website: HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: P...

July 25, 2022 1 EN
 PRESS RELEASE
Free
PSTI Pluristem Thera...

Pluristem Reports Topline Results from its Phase III Study of Muscle R...

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: HAIFA, Israel, July 13, 2022 (GLOBE NEWSWIRE) -- (Nasdaq:PSTI) (TASE:PSTI) (“Pluristem” or the “Company”), a leading biotechnology company, today announced topline results from its multinational double-blind, placebo-controlled phase III study. The Company designed the study to determine t...

July 13, 2022 1 EN
 PRESS RELEASE
Free
PSTI Pluristem Thera...

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partne...

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: HAIFA, Israel, March 28, 2022 (GLOBE NEWSWIRE) --  (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”), a leading biotechnology company, and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today announced that Pluristem’s CEO and President Yaky Yanay and Tnuva Group’s Chairman, Haim Gavrieli...

March 28, 2022 1 EN
 PRESS RELEASE
Free
PSTI Pluristem Thera...

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show...

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a favorable safety profile.PLX-R18 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the of graft failure and incomplete hematopoietic recovery following HCT and the prevention ...

March 23, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch